BACKGROUND: Two regimens are used to achieve excellent glycemic control during pregnancy in type 1 diabetes mellitus (T1DM): continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI). We assessed their efficacy and safety and the effect of pregnancy planning. METHODS: We examined 269 pregnant T1DM women: 157 treated with MDI (MDI group), 42 with CSII (CSII group), and 70 who switched from MDI to CSII in the first trimester (MDI/CSII group). There were 116 women who planned pregnancy: 58 in the MDI group, 38 in the CSII group, and 20 in the MDI/CSII group. The estimated differences in glycemic control and maternal and fetal outcomes were adjusted for baseline characteristics. RESULTS: Mean glycated A1c (HbA1c) in the first trimester in the whole group was 6.9%, and the women differed depending on whether they planned pregnancy or not (P < 0.0001). A multiple regression model showed an average difference of about 0.9% in favor of pregnancy planning, with no interaction between the planning and treatments. In the second trimester, HbA1c decreased to a mean value of 5.8%, with improvement of HbA1c across all treatments: by 1.5% in not-planning and 0.9% in planning women. Despite greater improvement, not-planning women still had a higher HbA1c (by 0.3%, P = 0.05). In the third trimester, there was no further significant changes; nevertheless, women who planned pregnancy still had a lower HbA1c (by 0.5%, P = 0.02). There were 14 malformations, stillbirths, and perinatal infant deaths in the not-planning versus five in the planning group (P = 0.07). Patients in the CSII group had a 2 kg greater weight gain compared to the MDI group (15.0 kg vs. 13.0 kg; P = 0.005). CONCLUSIONS: In pregnancy with T1DM, both MDI and CSII can provide excellent glycemic control. Pregnancy planning has a beneficial effect on glycemic control, independent from the therapy model. CSII seems to predispose to a larger weight gain in mothers.
BACKGROUND: Two regimens are used to achieve excellent glycemic control during pregnancy in type 1 diabetes mellitus (T1DM): continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI). We assessed their efficacy and safety and the effect of pregnancy planning. METHODS: We examined 269 pregnant T1DM women: 157 treated with MDI (MDI group), 42 with CSII (CSII group), and 70 who switched from MDI to CSII in the first trimester (MDI/CSII group). There were 116 women who planned pregnancy: 58 in the MDI group, 38 in the CSII group, and 20 in the MDI/CSII group. The estimated differences in glycemic control and maternal and fetal outcomes were adjusted for baseline characteristics. RESULTS: Mean glycated A1c (HbA1c) in the first trimester in the whole group was 6.9%, and the women differed depending on whether they planned pregnancy or not (P < 0.0001). A multiple regression model showed an average difference of about 0.9% in favor of pregnancy planning, with no interaction between the planning and treatments. In the second trimester, HbA1c decreased to a mean value of 5.8%, with improvement of HbA1c across all treatments: by 1.5% in not-planning and 0.9% in planning women. Despite greater improvement, not-planning women still had a higher HbA1c (by 0.3%, P = 0.05). In the third trimester, there was no further significant changes; nevertheless, women who planned pregnancy still had a lower HbA1c (by 0.5%, P = 0.02). There were 14 malformations, stillbirths, and perinatal infant deaths in the not-planning versus five in the planning group (P = 0.07). Patients in the CSII group had a 2 kg greater weight gain compared to the MDI group (15.0 kg vs. 13.0 kg; P = 0.005). CONCLUSIONS: In pregnancy with T1DM, both MDI and CSII can provide excellent glycemic control. Pregnancy planning has a beneficial effect on glycemic control, independent from the therapy model. CSII seems to predispose to a larger weight gain in mothers.
Authors: Eleanor Bimla Schwarz; Debbie Postlethwaite; Yun-Yi Hung; Eric Lantzman; Mary Anne Armstrong; Michael A Horberg Journal: J Gen Intern Med Date: 2011-09-16 Impact factor: 5.128
Authors: Katarzyna Cyganek; Alicja Hebda-Szydlo; Jan Skupien; Barbara Katra; Izabela Janas; Alicja Borodako; Irena Kaim; Tomasz Klupa; Alfred Reron; Maciej T Malecki Journal: Endocrine Date: 2011-04-29 Impact factor: 3.633
Authors: Melissa M Kallas-Koeman; Jason M Kong; Jennifer A Klinke; Sonia Butalia; Abhay K Lodha; Ken I Lim; Qiuli M Duan; Lois E Donovan Journal: Diabetologia Date: 2014-01-17 Impact factor: 10.122
Authors: K J Neff; R Forde; C Gavin; M M Byrne; R G R Firth; S Daly; F M McAuliffe; M Foley; M Coffey; S Coulter-Smith; B T Kinsley Journal: Ir J Med Sci Date: 2013-10-22 Impact factor: 1.568
Authors: Katarzyna Cyganek; Jan Skupien; Barbara Katra; Alicja Hebda-Szydlo; Izabela Janas; Iwona Trznadel-Morawska; Przemysław Witek; Elżbieta Kozek; Maciej T Malecki Journal: Endocrine Date: 2016-10-11 Impact factor: 3.633
Authors: Katarzyna Cyganek; Alicja Hebda-Szydlo; Jan Skupien; Izabela Janas; Joanna Walczyk; Anna Lipowska; Sebastian Borys; Maciej T Malecki Journal: Diabetes Care Date: 2012-12-18 Impact factor: 19.112